

Table S1: Cardiovascular events in TAVI studies (RCTs and registries) since 2016

Trial	Year	Study Type	Number of patients	STS score	Pre-existing AF	Life-threatening or major bleeding		Stroke/TIA		Myocardial infarction		All-cause death	
						30 days	1 year	30 days	1 year	30 days	1 year	30 days	1 year
PARTNER 2A	2016	RCT	1011	5.8±2.1	31.0%	10.4% ^b	15.2% ^b	5.5% / 0.9%	8.0% / 2.4%	1.2%	2.5%	3.9%	12.3%
SURTAVI	2017	RCT	864	4.4±1.5	28.1%	12.2%	N/A	3.4% / 1.5%	5.4% / 3.2%	0.9%	2.0%	2.2%	6.7%
REPRISE II	2018	RCT	912	6.8	33.9%	12.1%	18.0%	4.6% / N/A	7.9% / N/A	0.9%	3.6%	2.2%	12.4%
PARTNER 3	2019	RCT	496	1.9±0.7	15.7%	3.6% ^c	7.7% ^c	0.6% / 0%	1.2% / 1.0%	1.0%	1.2%	0.4%	1.0%
Evolut Low Risk	2019	RCT	734	1.9±0.7	15.5%	2.4% ^b	3.2% ^b	3.4% / 0.6%	4.1% / 1.7%	0.9%	1.7%	0.5%	2.4%
SCOPE 1	2019	RCT	739	3.5 [2.6-5.0]	36.4%	13.1%	N/A	2.4% / 0.5%	N/A	0.3%	N/A	1.6%	N/A
FRANCE 2	2016	Registry	4201	N/A	26.4%	8.6% ^d	10.4% ^d	2.3% / N/A	2.9% / N/A	0.9%	1.3%	9.2%	23.2%
STS/ACC TVT	2017	Registry	21575	6.8 [4.5,10.3]	41.2%	8.6%	N/A	2.5% / N/A	4.1% / N/A	0.8%	2.2%	6.1%	22.1%
SOURCE 3	2017	Registry	1946	N/A	22.6%	5.0% ^b	N/A	1.4% / 0.6%	3.1% / 1.2%	0.3%	0.9%	2.2%	12.6%
Swiss TAVI	2018	Registry	3493	5.8±4.4	N/A	13.4%	15.3%	3.8% ^e	4.9% ^e	0.6%	1.4%	3.8%	12.8%
WIN-TAVI	2018	Registry	1019 ^a	8.3±7.4	20.0%	12.5%	12.8%	1.3% / N/A	2.2% / N/A	0.2%	1.1%	3.9%	12.5%
FORWARD	2018	Registry	1060	5.5±4.5	34.5%	9.9%	10.7%	2.8% / 0.4%	3.4% / 1.1%	0.8%	1.8%	1.9%	8.9%
GARY	2019	Registry	6062	2.86±0.72	18.8%	N/A	N/A	N/A	N/A	N/A	N/A	1.8%	10.0%
FRANCE TAVI	2019	Registry	11469	N/A	33.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9.6%

^a women only. ^b life-threatening or disabling bleeding. ^c bleeding events were assessed using the trial criteria. ^d major bleeding. ^e Stroke and TIA combined.

AF: Atrial fibrillation. N: number of study participants. N/A: not available. RCT: randomised controlled trial. STS score: Society of Thoracic Surgeons predicted risk of mortality. TAVI: transcatheter aortic valve implantation. TIA: transient ischemic attack.